For most of the last two decades, a young adult diagnosed with IgA nephropathy heard a version of the same conversation: control your blood pressure, take a blood pressure medication that also protects the kidneys, watch your protein levels, and hope. Roughly half of patients progressed to kidney failure.
That conversation has changed faster in the past nine months than in the previous twenty years. The FDA approved atacicept, sold as Trutakna, on July 7, 2026, following the approval of sibeprenlimab in late 2025. Two additional drugs now sit before the agency with decisions expected before the end of December.
IgA nephropathy, also called Berger's disease, is often diagnosed in people in their twenties and thirties, frequently after blood is spotted in the urine or protein turns up on a routine test. That timing is what makes the shift consequential. A patient diagnosed at 28 is looking at a treatment landscape that may look nothing like the one their doctor trained on.
The Approval That Landed in July
Atacicept is a once-weekly injection that patients give themselves at home using an autoinjector. It blocks two immune signaling proteins, BAFF and APRIL, which drive the B cells that produce the abnormal antibody at the root of the disease. It is the first approved medicine to block both.
The approval rests on an interim analysis of the ongoing ORIGIN 3 trial, which enrolled 431 adults with biopsy-confirmed disease and randomly assigned them to atacicept or placebo. In the first 203 patients to reach the nine-month mark, those on the drug had a 46 percent average reduction in protein in the urine.
Sibeprenlimab, sold as Voyxact and cleared by the FDA in November 2025, works on APRIL alone. Both are given by injection. Both target the disease process itself rather than managing its downstream effects, which is the genuine break from older care.
Proteinuria Is a Stand-In, Not the Outcome That Matters Most
Here is the limitation that belongs at the front of any conversation about these drugs, not buried at the end.
Both approvals came through the FDA's accelerated approval pathway, which allows a drug onto the market based on a surrogate measurement rather than the outcome patients actually care about. The surrogate here is proteinuria. The outcome that matters is whether kidneys keep working and whether dialysis or transplant is avoided.
The FDA states this plainly in its own announcement: "It has not been established whether Trutakna slows kidney function decline" over the long term in these patients. Continued approval may depend on the confirmatory portion of ORIGIN 3, which is still running in a blinded, placebo-controlled fashion and is expected to report kidney function data using estimated glomerular filtration rate.
Lower protein in the urine has been associated with slower kidney decline across many studies. That association is the reason regulators accepted it. It is not proof, and any patient told a drug will save their kidneys is being told more than the evidence currently supports.
On safety, atacicept suppresses the immune system and may raise infection risk. The FDA advises assessing patients for active infection before starting and monitoring during treatment. Live vaccines are not recommended within 30 days before starting or during treatment, which is a real scheduling consideration for anyone planning travel or catching up on immunizations.
Two More Decisions Before the End of the Year
Vertex Pharmaceuticals has an application pending for povetacicept, another dual BAFF and APRIL blocker, with an FDA target date of November 30, 2026. Its phase 3 RAINIER trial enrolled 605 adults and reported a 52 percent reduction in urinary protein at 36 weeks in an interim analysis.
Alexion and AstraZeneca have an application pending for ravulizumab, marketed as Ultomiris and already approved for several other conditions, with a decision anticipated in the fourth quarter of 2026. It works on a different system entirely, blocking part of the complement cascade rather than B cell signaling. In the phase 3 I CAN trial, protein in the urine fell 46.6 percent at 34 weeks against 5.6 percent on placebo.
Neither is approved. Neither can be prescribed for this condition today. Both interim analyses were reported by the manufacturers, and the FDA can approve, decline, or request more data in each case.
Questions Worth Raising at the Next Nephrology Visit
A newly diagnosed patient walking into an appointment now has more to ask about than a patient did two years ago, and the questions are different.
Whether a kidney biopsy has confirmed the diagnosis matters, because these drugs were studied in biopsy-confirmed disease. Whether current proteinuria and kidney function put someone in the "at risk for progression" group named in the labels matters, because that is who was studied. Whether a blood pressure medication and an SGLT2 inhibitor are already optimized matters, because trial participants were on background therapy, not instead of it.
Timing is also worth raising. Two decisions are expected within months, and a nephrologist may have a view on whether waiting is reasonable or whether starting now is the better call for a particular patient. Clinical trial enrollment is another route worth asking about directly.
Nobody should start, stop, or change any medication based on a news article. These are immune-modifying injections with real infection risk, and the decision belongs to a nephrologist who knows the individual case.
Coverage, Cost, and the Practical Access Problem
More options do not automatically mean more access. Specialty biologics for rare kidney disease typically require prior authorization, and plans commonly ask for documentation of biopsy confirmation, proteinuria levels, and failure or intolerance of standard therapy before approving.
Patients facing a denial can ask their nephrology practice about the appeals process, about manufacturer patient assistance programs, and about whether a different approved agent has a smoother path on their formulary. Practices that treat glomerular disease regularly often have staff dedicated to this work, which is a reason to seek care at a center with that experience where geography allows.
Nonprofit organizations focused on protein-spilling kidney disease, including NephCure and the IgA Nephropathy Foundation, maintain specialist directories and patient support resources. Bonnie Schneider, director and cofounder of the IgA Nephropathy Foundation, said in a sponsor announcement that she has "never had more hope for the future" given what is in development, a patient-advocacy perspective that came through a company release rather than independently.
The bottom line: two disease-targeted drugs are now approved for IgA nephropathy and two more face FDA decisions by December, but every approval so far rests on protein reduction rather than proven kidney preservation. The most affected group is young adults facing decades of disease. The most reasonable step is a detailed conversation with a nephrologist about biopsy status, risk category, and timing. MedicalDaily will report the November and fourth-quarter FDA decisions.
Frequently Asked Questions
What is IgA nephropathy? A kidney disease in which an abnormal form of the antibody immunoglobulin A builds up in the kidneys, causing inflammation and damage. Protein leaks into the urine and kidney function can decline over time.
Which drugs are approved right now? Sibeprenlimab, approved in November 2025, and atacicept, approved July 7, 2026. Both are injections that target the immune process driving the disease.
Do these drugs prevent kidney failure? That has not been established. Both were approved based on reducing protein in the urine, which is a surrogate marker. Confirmatory trials measuring long-term kidney function are still running.
What is coming next? Povetacicept has an FDA target date of November 30, 2026, and ravulizumab has a decision anticipated in the fourth quarter of 2026. Neither is approved for this condition today.
What are the main safety concerns? Atacicept suppresses the immune system and may increase infection risk. Patients should be checked for active infection before starting, monitored during treatment, and should avoid live vaccines within 30 days before or during therapy.
Should I ask my doctor to switch me to one of these? Bring it up, but do not change anything on your own. Whether any of these fits your case depends on biopsy results, current kidney function, proteinuria level, and what you are already taking.
Where can I find a specialist or a trial? Ask your nephrologist about referral to a center that treats glomerular disease, and about open clinical trials. Nonprofit patient organizations focused on rare kidney disease also maintain specialist directories.
